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The response of androgen-sensitive Noble (Nb) rat prostatic adenocarcinoma C2Pr-121 D 
(1») to varying doses (50~1,000,ug/kg body weight) of diethylstilbestrol (DES) was investiga-
ted and characterized with respect to cytosol and nuclear androgen binding profiles. histology 
and pattern of relapse. Inhibition of tumor growth was closely related to the dose of DES. 
Treatment at all but the lowest dose (50,ugikg) initially caused tumor regression, whereas 
serum testosterone concentrations in all groups, including that receiving the lowest dose, 
were decreased to castrate levels. Histologically, while extensive cellluar destruction was 
clearly evident at higher doses of DES, some active tumor cells appeared to survive. Tumors 
eventually relapsed when higher doses of DES were stopped or with the continued administra-
tion of low doses. The cytosol dihydrotestosterone (DHT) receptor in this tumor line, as 
determined by sucrose density gradient, dextran charcoal and Sephadex column methods, was 
negative. Nuclear binding, however, was positive. Salt-extractable and salt-resistant fractions 
of nuclei derived from the untreated primary tumor and relapsed tumor following DES 
treatment contained high affinity androgen receptor. Comparison of binding constants 
revealed no significant differences. Our findings, based on the Nb rat prostatic tumor model, 
indicate that DES acts not only by eliminating circulating testosterone, but also by a direct 
cytotoxic effect on malignant cells. The results also suggest the lack of an apparent relation-
ship between the loss of hormone responsiveness associated with recurrence of prostatic tumor 
growth and nuclear androgen binding parameters. 
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INTRODUCTION 
After an initial suppression of growth 
following the removal of androgen support, 
most prostatic cancers relapseD. This re-
currence of growth has been attributed to 
the survival and subsequent multiplication 
of androgen-insensitive cells that resist 
androgen-ablation measures2). Clinically, 
diethylstilbestrol (DES) is an alternative 
form of therapy to metastatic prostatic 
cancer. The rationale for the endocrine 
treatment is mainly to lower circulating 
testosterone to castrate levels, thereby re-
moving the stimulus to androgen depen-
dent growth. However, the observation 
that the response to high-dose estrogen 
therapy achieved by patients no longer 
responsive to standard dose estrogen the-
rapy would suggest that an additional 
cytotoxic effect at the cellular level is 
involved3,4), 
In the present study, the Noble (Nb) 
rat model of androgen-sensitive prostatic 
adenocarcinoma was chosen to investigate 
the effect of DES on tumor growth and 
the pattern of relapse subsequent to the 
discontinuation of high dose of DES. We 
have also investigated possible changes in 
nuclear androgen binding characteristics 
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associated with recurrent tumor growth. 
MATERIALS AND METHODS 
Animals and tumors-The animals used 
in this study were male Nb rats, originally 
obtained from Dr. J. Drago, Milton S. 
Hershey Medical Center, Pennsylvania 
State University, Hershey, PA. The ani-
mals were housed in polycarbonate cages 
and maintained on Purina rat chow and 
water. The Nb rat prostatic adenocarci-
noma C2Pr-121D (1)J, sensitive to andro-
gens, was supplied by Dr. A.E. Bogden, 
Mason Research Institute, Worcester, MA. 
The tumor was maintained by serial pas-
sages 10 young (7 ~8 weeks old) male Nb 
rats. 
Implantation of tumor (2 mm3 pieces) 
was performed with a trocar needle into 
both flanks of the host animals. Treat-
ment with DES was initiated when the 
average tumor diameter was approximately 
10 mm. The rats were randomly distribu-
ted into the following groups: 
1. Untreated controls 
2. 50 pg/kg body weight 
3. 100 "" "" "" "" 
4. 200 "" "" -'/ "" 
5. 300 "" "" -'/ "" 
6. 500 "" "" -'/ "" 28 days---->IOO 
pg/kg 
-'/ 23 days----> 
treatment stopped 
7. 1000 
Each group contained 5 rats, bearing 
bilateral tumors. DES (Sigma Chemical 
Co., St. Louis, MO), in sesame oil-lO% 
ethanol, was administered daily by sub-
cutaneous injections. Tumor measurements 
(length and width) were conducted twice 
weekly with the use of a Vernier micro-
caliper. 
The animals in Groups 2~5 were treated 
for 22 days, at which time they were killed, 
along with the untreated control rats 
(Group 1). Rats in Group 6 and 7 were 
treated for 54 and 62 days, respectively. 
At the time of sacrifice, blood was removed 
by cardiac puncture and tumor excised 
and cryopreserved for later biochemical 
analyses. In addition to the tumors, testes 
and prostate were removed and their weights 
recorded. Pieces of each tumor tissue 
were preserved for histology. 
Nuclear preparation and fractionation-
Two procedures for the purification of 
nuclei were tested. In the first, nuclei 
were prepared in isotonic sucrose, as 
previously described5). In the second 
procedure, minced tissue was homogenized 
in 0.5% citric acid, a procedure reported 
to be particularly suited for the prepara-
tion of nuclei from tumor tissue6). Follow-
ing centrifugation at 800 x g, crude nuclei 
obtained by both procedures were subject-
ed to one hour centrifugation through 2.2 
M sucrose at 70,000 x g. Nuclei prepared 
by the sucrose method, as observed by 
light microscopy, were intact but contami-
nated with cytoplasmic debris. On the 
other hand, nuclei prepared in citric acid 
were relatively free of cytoplasmic tags 
but evidently damaged, as judged by irre-
gularities in size and shape and some 
leakage of nuclear content. 
Nuclei were sub-fractionated essentially 
according to the procedure outlined by 
Ekman et al7). All steps were carried out 
at DoC. Briefly, the crude nuclear prepara-
tion was suspended in buffer consisting of 
10 mM Tris, 1.5 mM ethylenediaminetetra-
acetate (EDT A), 1 mM dithiothreotol 
(DTT) and 10% (wt/vol) glycerol, pH 7.48) 
plus 1 mM freshly added phenylmethylsul-
fonyl fluoride (PMSF). Following ex-
traction with 1% Triton-X-100 and two 
washes with the buffer, the nuclear pellet 
was digested with pancreatic deoxyribo-
nuclease (20 pg/ml in 10 mM Tris, pH 7.4, 5 
mM, MgCI, 1 mM DTT and 1 mM PMSF) 
for 30 min. Following centrifugation, the 
nuclear pellet was extracted with 10 mM 
Tris, pH 7.4, 1 mM EDTA, 1 mM DTT, 0.6 
M KCI and 1 mM PMSF. After 30 min., 
centrifugation at 1,000xg for 15 min., 
yielded the "salt-extractable" fraction and 
a residual pellet. The pellet, upon suspen-
sion in 10 mM Tris, pH 7.4, 1.5 mM EDT A, 
1 mM DTT and 1 mM PMSF, constituted 
the "salt-resistant" fraction. 
Androgen binding analysis-Assays to 
characterize cytoplasmic androgen receptor 
were previously described5), as was the 
preparation of the cytosol fraction. In the 
nuclear binding assay, 0.5 ml of nuclear 
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subfraction was incubated in triplicate 
tubes with 5 concentrations (3~ 18 nM) of 
1 ,2,5,6,7-3H (N) -dihydrotestosterone (DHT), 
specific activity 123 Ci/mmole (New Eng-
land Nuclear, Boston, MA) in the presence 
and absence of 200-fold excess unlabeled 
DHT (Steraloids, Inc., Wilton, NH). After 
20 hours at 4°C, the incubation was termi-
nated and the samples assayed by the 
Dextran charcoal method?). To each tube, 
0.5 ml suspensions of 0.5% (wt/vol) char-
coal and 0.025% dextran in incubation 
buffer was added. After 20 min., at 4°C, 
with gentle mixing, the charcoal was cen-
trifuged at 10,000 x g for 5 min, and the 
supernatant transferred to counting vials. 
Ten ml of scintillation fluid (ACS II, 
Amersham Corp., Arlington, IL.) was add-
ed and the radioactivity measured in a 
Packard 3,375 spectrometer,with a counting 
efficiency of approximately 45% for 2H. 
Total binding and non-specific binding 
were estimated by saturation analysis. 
Specific binding was obtained from the 
difference. 
Other methods-Protein content was 
measured by the method of Lowry et al.q), 
serum testosterone concentrations were 
determined by radioimmunoassay, using a 
kit obtained from Endo-Tech, Inc., Louis-
ville, KY. For histology, pieces of tissues 
were fixed in Bouin's solution and stained 
with hematoxylin and eosin. 
RESULTS 
Effect of DES on body and tissue 
weights-
Fig. 1 shows the changes in body and 
tissue weights produced by DES treatment. 
The untreated rats showed an average gain 
in body weight of 17%. At the highest 
dose (1,000 flg/kg body wt.), there was a 
17% loss in body weight. The decrease 
in tumor size and weight at day 22 were 
moderate at 50 flg/kg DES (75% and 55% 
of untreated control value, respectively). 
Higher doses produced further inhibition, 
although 200 and 300 flg/kg doses were 
only slightly more effective, but not signi-
ficantly different from the 100 flg/kg dose. 
Tumor dimensions at 100, 200 and 300 
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Fig. 1. Effect of DES treatment on final body 
and tissue weights. Open bar, body 
weight; cross-hatched bar, testes; dashed 
bar, ventral prostate; dotted bar, dorso-
lateral prostate; closed bar, prostatic 
tumor. N =5 for body weight and all 
tissue weights, except for tumor weight, 
N for which was 10. 
respectively. Corresponding values in ave-
rage final tumor weight were 12, 11 and 
5 % of the control, respectively. The 
actual values of mean tumor diameter (in 
mm) at day 22 were as follows: Untreated, 
18.5±0.9; 50 flg/kg DES, 13.9±1.6 (p< 
.025); 100 fig/kg, 10.1 ±0.5 (p<.OOl); 200 
fig/kg, 8.6±0.3 (p<.OOl); 300 fig/kg, 8.4± 
0.8 (p<.OOl). 
Growth curves-
All tumors were approximately 1 cm in 
diameter at the beginning of the experi-
ment. The tumors in the untreated rats 
(Group 1) increased 85% in mean tumor 
diameter in 3 weeks (Fig. 2). Based on 
the value on day 22, all of the DES-treated 
groups showed inhibition of growth, the 
degree of which was in the order of in-
creasing dose. With exception of the lowest 
dose (50 fig/kg, Group 2), tumor regression 
was observed at all doses. In animals 
treated with 100, 200 and 300 fig/kg DES 
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Fig. 2. Growth inhibitory response of prostatic 
tumor to DES. Average tumor diameter 
was determined from length and width 
and the mean initial average tumor 
diameter within each group was normali-
zed to 1.0. Closed circle, untreated cont· 
rol group; open circle, 50 pg/kg; closed 
triangle, 100 pg/kg; open triangle, 200 
fIg/kg; closed inverted triangle, 300 pg/ 
kg; open inverted triangle, 500 pg/kg 
reduced to 100 pg/kg at day 28; closed 
square, 1,000 pg/kg for 23 days. Each 
group consisted of 5 rats, with each 
animal bearing bilateral tumors. Bars 
represent standard error. 
(groups 3 to 5) the tumor begn to relapse 
10 days after the initiation of treatment. 
When DES at 1,000 pg/kg was stopped, 
tumors immediately relapsed (Group 7). 
Similarly, when the 500 pg/kg dose was 
reduced to 100 pg/kg, relapse occurred 
(Group 6) although at a slower rate. Some 
atypical observations in Group 6 included 
the complete disappearance (undetectable 
by palpation) of 3 tumors, 2 of which 
reappeared and grew. The remaining tumor 
did not recur during the observation period 
of 120 days. 
In rats treated with 500 and 1,000 pg/kg 
DES, the reduction in tumor size was 
significantly accelerated, such that at day 
22, the values were 30 and 16% of the 
control, respectively (Fig. 2). 
Serum testosterone concentration-
Table 1. Serum testosterone levels in 
DES-treated Nb rats 
Group DES,ug/kg ng/lOOmI 
Intact 0 422.7±83.3 
Castrated 0 2.4± 0.5 
Intact 50 1.7± 0.5 
Intact 100 0.9± 0.5 
Intact 200 2.9± 1.0 
Intact 300 1.4± 0.4 
Values are means for ~pJes from 4 rats 
per group ± S.e. 
Table I shows the effect of DES treat-
ment on serum concentration of testoste-
rone. Orchiectomy decreased circulating 
testosterone to less than I % of control, 
as expected. A strong anti-gonadal effect 
of DES, as reflected by the greater than 
40% reduction of testes weight by day 22 
(Fig. 1) was confirmed in all the treated 
groups. Even at the lowest dose (50 pg/ 
kg), serum testosterone fell to a value 
similar to that measured in castrated 
animals. 
Cytosol androgen receptor analysis-
Fig. 3A shows the results of the assay for 
the presence of an androgen receptor in 
the cytosol fraction of prostatic and tumor 
tissues by sucrose density gradient centri-
fugation. Cytosol prepared from ventral 
prostates of I-day castrated Nb rats con-
tained an 8S DHT binding peak. By 
contrast, no such peak was detected when 
the cytosol preparation from the androgen-
sensitive prostatic tumor was incubated 
with radio labeled DHT. In view of this 
negative finding, two other conventional 
methods of discriminate specific, high affi-
nity receptor binding sites were utilized. 
Fig. 3B shows the results of quantitation 
by the dextran-coated charcoal method. 
In these experiments, molybdate was added 
to ensure stabilization of receptor protein 
and PMSF was added to minimize pro-
teolytic degradation. Compared to the 
ventral prostate cytosol, which served as 
a control for the presence of specific DHT 
receptor, the binding activity present in 
the tumor cytosol was not displaced by 
excess non-radioactive DHT ligand. The 
third methods of analysis, by gel filtration 
through a Sephadex G-25 column (not 
shown), confirmed the results obtained 
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Fig. 3. Cytosol androgen receptor determinations. DHT binding was measured by sucrose 
density gradient (A) and dextran-charcoal method (B). Closed circle, prostate 
cytosol incubated with 3H-DHT; open circle, prostate cytosol incubated with 
3H-DHT plus excess unlabeled DHT; closed triangle, prostatic tumor cytosol 
incubated with 3H-DHT; BSA, bovine serum albumin. Closed bar, 3H-DHT; 
open bar, 3H-DHT plus excess unlabeled DHT; MoO.=, molybdate; PMSF, 
phenylmethylsulfonyl fluoride. 
with the charcoal method. Thus, the 
high affinity cytosol receptor, specific for 
DHT, was not detectable in the Nb 
rat prostatic adenocarcinoma used in this 
study. 
Nuclear androgen receptor analysis-
Preliminary nuclear binding assay was 
carried out on high salt-extractable and 
-resistant fractions on nuclei prepared by 
isotonic sucrose or citric acid method, 
each followed by centrifugation through 
2.2 M sucrose. Nuclei prepared with iso-
tonic sucrose were intact, but attached 
with cytoplasmic tags, whereas those pre-
pared with citric acid were relatively free 
of cytoplasmic contamination, but showed 
some damage and extrusion of nuclear 
material (not shown). Fig. 4 shows that 
high affinity DHT binding sites could 
be demonstrated in subfractions of nuclei 
prepared by both methods. An exception 
was the salt-resistant fraction of nuclear 
obtained in citric acid. Essentiallv similar 
results were obtained when the sub-
nuclear fractions were extracted for crude 
preparations of nuclei and examined for 
DHT binding. 
The apparent absence of specific andro-
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Fig. 4. Measurement of 3H-DHT binding in 
unclear fractions of prostatic tumor. 
Nuclei were prepared in isotonic sucrose 
(top) or citric acid (botton). Dashed 
portion of bars represents non-specific 
binding; open portion of bars indicates 
specific binding. 
least in our androgen-sensitive Nb rat 
prostatic tumor line and under our con-
ditions of assay (Fig. 3), precluded the 
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Table 2. Androgen binding characteristics in nuclear sub-fractions of untreated 
and DES-treated recurrent Nb rat prostatic tumor 
Nuclear sub· fraction Exp. No. Primary Tumor Relapsed Tumor 
K (nM) B (pM) K (nM) B (pM) 
~-- -max-- ~-- -max--
Salt·extractable 7.2 80.0 4.3 18.0 
(0.6 M KCl·soluble) 2 . 1.1 16.8 8.7 248.4 
3. 3.4 26.8 4.2 53.2 
Salt·resistant 7.4 44.4 
(matrix·bound) 2. 6.7 83 .0 15.9 137.0 
3. 0.7 36.6 10.4 33.2 
Results from 3 separate determinations are reported for each of untreated 
(primary) tumor and relapsed tumor following DES treatment. 
Fig. 5. Representative histology of prostatic tu-
mor in untreated Nb rat. Sections cha-
racteristic of control tumor included 
(A) solid sheet of malignant cells and 
(B) other areas with glandular elements. 
Hematoxylin and Eosin, x 240. 
need for highly purified nuclei. All subse-
quent nuclear binding assays were per-
formed on sub-fractions on relatively crude 
preparations of nuclei. The validity of 
the assay method was confirmed by satura-
tion analysis. High affinity, low capacity 
binding for DHT ligand was demonstrated 
in both high salt-extractable and salt-resist-
ant fractions. 
Table 2 shows the binding constants 
derived from Scatchard plots. Even though 
the mean Kd and Bmax values tended 
to be slightly higher for tumor tissues 
that had undergone relapse, the individual 
values among groups were highly variable. 
Fig. 6. R epresentative histology of prostatic 
tumor in DES-treated rat. Sections were 
of regressed tissue following 500 pg/kg 
DES for 22 days. A, reduction in cellu-
lar mass with relative increase in edema-
tous stroma; B, degenerative changes 
showing cell debris and pyknotic nuclei. 
Hematoxylin and Eosin, X 240. 
Consequently, no significance could be 
attached to differences between untreated 
tumors and tumors of recurrent gowth in 
either the high salt-extractable or -resistant 
nuclear fraction. 
Histology-
Figs. 5 and 6 show the histological pat-
terns of Nb rat prostatic adenocarcinoma. 
The androgen-sensitive tumor from an 
untreated rat (Fig. 5) was composed of a 
mixture of dense mass of poorly differen-
tiated cells with scant stroma (5A) and 
areas of small glandular and pseudogh l1 . 
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dular formations (5B). At 50 pg/kg of 
DES, a dose which lowered the serum 
testosterone to castrate levels but did not 
suppress tumor growth, the histological 
appearance of the tumor was virtually 
unchanged (not shown). At 500 pg/kg, 
DES treatment for 22 days caused marked 
changes in the regressed tumor (Fig. 6). 
In some regions, the histology was charac-
terized by small and diffuse groups of 
cells, widely separated by extensive areas 
of fibrous and mucoidal stroma (6A). 
In other areas, extensive regressive changes 
were apparent (6B). Remnants of cellular 
fragments and pyknotic nuclei were clearly 
visible. It was also evident that not all 
malignant cells were destroyed in this re-
gressed tissue. Irregular nests of surviving 
cells remained. In the relapsed tumor, 
the histological appearance reverted to that 
of the untreated tumor, with the cells 
arranged in tightly packed cords separat-
ed by thin intervening stroma (not shown.) 
DISCUSSION 
The beneficial effect of DES in the 
treatment of cancer of the prostate is well 
known3,4,lo-m. While it probably has 
several modes of action, DES acts primari-
ly by suppressing the release of pituitary 
LH, thereby interfering with the gonadal 
production of testosteroneI3- 1S)" Among 
other effect of DES, a direct cytostatic 
action at the cellular level cannot be ruled 
out. In the present study, even the lowest 
(50 pg/kg) dose of DES was sufficient to 
maximally lower serum testosterone to 
castrate levels. Since lower doses of DES 
failed to arrest tumor progression, it is 
apparent that DES, at high doses, caused 
tumor regression by a mechanism other 
than by simply abolishing circulating tes-
tosterone. 
The Nb rat prostatic tumor line was 
partially dependent on androgen, as indi-
cated by its sub-optimal growth in the 
female and castrated male rats I6). In the 
present study the reduction in the overall 
tumor mass with DES treatment would 
suggest that androgen-insensitive cells as 
well as androgen-sensitive cells responded. 
This observation provides further evidence 
that the fall m serum testosterone levels 
via the anti-gonadal effect cannot solely 
account for the growth inhibitory action 
of DES. 
While our data indicate that the effIcacy 
of DES cannot be due exclusively to an 
indirect effect via the pituitary-gonadal 
axis, a direct cytotoxic effect was clearly 
apparent in some histological sections. 
Moreover, the histology of regressed tissues 
showed some malignant cells resisted 
DES treatment. These remaining active 
cells may well represent clones from which 
malignancy is renewed and thereby ac-
count for the eventual recurrence of prost a-
tic tumor growth2,IO). 
The high variability in the response of 
prostatic cancer to anti-androgen therapy 
and the eventual progression to a state of 
hormone-insensitivity have been attributed 
to tumor cell heterogeneity2), Beginning 
with a mixture of pre-existing androgen-
dependent and -independent cells, tumor 
regression during DES treatment thus 
reflects the death of androgen dependent 
cells. The androgen-independent malig-
nant cells that survive the testosterone-
depleted environment and/or cytotoxic ac-
tion of DES and comprise the recurrent 
tumor might be expected to possess altered 
growth regulatory characteristics related 
to androgen sensitivity. 
Growth regulation by steroid hormones 
involves an interaction with cytoplasmic 
receptors. The translocation of steroid-
receptor complex to nuclear sites is pre-
requisite for the ultimate gene expression 
in the target cell17,18). In animal models 
of androgen-dependent carcinoma, com-
parative studies of dependent and indepen-
dent tumor lines revealed no correlation 
between tumor growth and cytosol andro-
gen receptor19 ,20). On the other hand, a 
relationship between nuclear salt-resistant 
receptor content and responsiveness to 
androgens was demonstrated20). The clini-
cal response of prostatic adenocarcinoma 
to endocrine therapy was also found to 
correlate with both salt-extractable and 
matrix-bound nuclear androgen binding2D • 
Despite these previous findings, our 
attempts to demonstrate significant diffe-
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rences in the nuclear androgen binding 
parameters between primary (androgen-
dependent) and relapsed (androgen-inde-
pendent) tumors in the Nb rat model were 
unsuccessful. The lack of absolute andro-
gen dependency in this prostatic tumor, in 
contrast to the Dunning R3327H tumors2l 
minimized any differences that may exist 
between the two growth phases. It is also 
possible that the secondary growth in these 
experiments does not represent a true 
relapse phenomenon, such as that observed 
in a clinical situation. Since a natural pro-
gression to a state of relapse would outlast 
the life span of the animal, DES treatment 
in this experimental system was either 
discontinued or reduced in dosage to allow 
the recurrence of the tumor. Under these 
condition, the probability that the relapsed 
tumor still contained a heterogenous po-
pulation of cells similar to the DES-untrea-
ted tumor cannot be ruled out. 
The biochemical changes associated with 
the progression of initially androgen-sensi-
tive prostatic cancer cells to an androgen-
insentivite state remain unclear. An under-
standing of the mechanism for this relapse 
following androgen ablation measures 
would be of great value in the design of 
clinical treatment and eradication of pro-
static cancer. 
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ア ン ドロゲ ソ反 応 性Nobleラ ッ ト前 立腺 癌(2Pr-
121D(1))を用 いて,こ れ に種 々の 量(50～1pooptg〆
kg)のジ エ チ ルス チ ル ベ ス テ ロー ル(DES)を 投 与
し,そ の影 響 を み た.血 清 テス トス テ ロソ値 は,す ぺ
て の 実験 群 に お い て去 勢 レベ ル に下 降 して いた が,腫
瘍 はDESの 量 が 多 い ほ ど強 く抑 制 され た.腫 瘍 は
DES投 与 中 に再 燃 を 開 始 し,ま たDESを 中 止 す る
と直 ちに再 燃 を起 こ した.DES投 与 に て 抑制 され た
腫 瘍 の組 織 像 は,癌 細 胞 の ほ と ん どが 死 滅 して い た が,
な お 一部 にactiveな腫 瘍 細 胞 が残 存 して いた.無 処
置 の 腫 瘍 の サ イ}・'7'1一ル のdihydr・testoster・ne
(DHT)レ セ プ タ ー は 蕪 糖 密 度 勾 配法,dextran-
coatedcharcoal吸着 法,ゲ ル 源過 クロ マ トグラ フ ィー
法 に て 測定 した が,い ず れ の 方 法 で も サ イ トゾール
DHTレ セ プ タ ーは存 在 し な か っ た.し か し 核 の
DHTレ セ プ タ ーを測 定 す る とDHTに 対 し高親 和
性 結 合 がみ られた.無 処置 の腫 瘍 と再 燃 した腫 瘍 の 核
DHTレ セ プ タ ー で は,salt-extractablefraction
とsalt-resistantfractionのKd.Bmaxはい ず れ
に お い て も差 は なか った.
以 上 の こ と か ら,こ のNobleラ ッ ト前 立 腺 癌 で
は,DESは 血 清 テ ス トス テ ロンを去 勢 レベ ル まで 低
下 させ る のみ な らず,前 立 腺 癌 細 胞 に対 して直 接 の殺
細 胞作 用 のあ る こ とが 示 唆 され た.DES投 与 中 の再
燃 癌 の 核 ア ソ ドロゲ ン レセ プ タ ーを 測定 した が,ホ ル
モ ソ依存 性 消 失 との関 係 は み いだ せ な か った.
